CORT
Income statement / Annual
Last year (2024), Corcept Therapeutics Incorporated's total revenue was $675.04 M,
an increase of 39.94% from the previous year.
In 2024, Corcept Therapeutics Incorporated's net income was $139.73 M.
See Corcept Therapeutics Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$675.04 M |
$482.38 M |
$401.86 M |
$365.98 M |
$353.87 M |
$306.49 M |
$251.25 M |
$159.20 M |
$81.32 M |
$50.29 M |
| Cost of Revenue |
$10.88 M
|
$6.48 M
|
$5.39 M
|
$5.28 M
|
$5.58 M
|
$5.50 M
|
$5.22 M
|
$3.55 M
|
$2.06 M
|
$1.36 M
|
| Gross Profit |
$664.16 M
|
$475.89 M
|
$396.47 M
|
$360.70 M
|
$348.29 M
|
$300.98 M
|
$246.03 M
|
$155.65 M
|
$79.26 M
|
$48.93 M
|
| Gross Profit Ratio |
0.98
|
0.99
|
0.99
|
0.99
|
0.98
|
0.98
|
0.98
|
0.98
|
0.97
|
0.97
|
| Research and Development Expenses |
$246.89 M
|
$184.35 M
|
$130.99 M
|
$113.86 M
|
$114.76 M
|
$89.02 M
|
$75.25 M
|
$40.38 M
|
$23.84 M
|
$15.42 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$280.32 M
|
$184.26 M
|
$152.85 M
|
$122.36 M
|
$105.33 M
|
$100.36 M
|
$81.29 M
|
$62.42 M
|
$45.24 M
|
$36.95 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$527.21 M
|
$368.61 M
|
$283.84 M
|
$236.22 M
|
$220.09 M
|
$189.38 M
|
$156.54 M
|
$102.79 M
|
$69.08 M
|
$52.37 M
|
| Cost And Expenses |
$538.09 M
|
$375.09 M
|
$289.22 M
|
$241.50 M
|
$225.67 M
|
$194.88 M
|
$161.75 M
|
$106.35 M
|
$71.14 M
|
$53.73 M
|
| Interest Income |
$24.54 M
|
$17.28 M
|
$3.56 M
|
$529,000.00
|
$3.40 M
|
$5.07 M
|
$2.66 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$3.56 M
|
$0.00
|
$0.00
|
$5.07 M
|
$2.66 M
|
$49,000.00
|
$2.04 M
|
$2.97 M
|
| Depreciation & Amortization |
$0.00
|
$1.04 M
|
$2.97 M
|
$3.07 M
|
$2.24 M
|
$2.17 M
|
$236,000.00
|
$106,000.00
|
$87,000.00
|
$155,000.00
|
| EBITDA |
$136.95 M |
$108.32 M |
$112.63 M |
$124.48 M |
$130.44 M |
$113.78 M |
$89.73 M |
$52.96 M |
$10.27 M |
-$3.29 M |
| EBITDA Ratio |
0.2
|
0.22
|
0.28
|
0.34
|
0.36
|
0.36
|
0.36
|
0.33
|
0.13
|
-0.07
|
| Operating Income Ratio |
0.2
|
0.22
|
0.28
|
0.34
|
0.36
|
0.36
|
0.36
|
0.33
|
0.13
|
-0.07
|
| Total Other Income/Expenses Net |
$24.54 M
|
$17.28 M
|
$3.56 M
|
$529,000.00
|
$3.40 M
|
$5.07 M
|
$2.66 M
|
-$49,000.00
|
-$2.04 M
|
-$2.97 M
|
| Income Before Tax |
$161.49 M
|
$124.56 M
|
$116.19 M
|
$125.01 M
|
$131.60 M
|
$116.68 M
|
$92.15 M
|
$52.81 M
|
$8.14 M
|
-$6.41 M
|
| Income Before Tax Ratio |
0.24
|
0.26
|
0.29
|
0.34
|
0.37
|
0.38
|
0.37
|
0.33
|
0.1
|
-0.13
|
| Income Tax Expense |
$20.28 M
|
$18.42 M
|
$14.77 M
|
$12.49 M
|
$25.59 M
|
$22.50 M
|
$16.74 M
|
-$76.32 M
|
$0.00
|
$0.00
|
| Net Income |
$139.73 M
|
$106.14 M
|
$101.42 M
|
$112.51 M
|
$106.01 M
|
$94.18 M
|
$75.41 M
|
$129.12 M
|
$8.14 M
|
-$6.41 M
|
| Net Income Ratio |
0.21
|
0.22
|
0.25
|
0.31
|
0.3
|
0.31
|
0.3
|
0.81
|
0.1
|
-0.13
|
| EPS |
1.35 |
1.02 |
0.95 |
0.97 |
0.92 |
0.82 |
0.6 |
1.14 |
0.07 |
-0.06 |
| EPS Diluted |
1.23 |
0.94 |
0.87 |
0.89 |
0.85 |
0.77 |
0.6 |
1.04 |
0.07 |
-0.06 |
| Weighted Average Shares Out |
$103.23 M
|
$103.56 M
|
$106.79 M
|
$115.65 M
|
$115.41 M
|
$114.35 M
|
$125.68 M
|
$113.53 M
|
$110.57 M
|
$106.80 M
|
| Weighted Average Shares Out Diluted |
$113.48 M
|
$111.74 M
|
$115.97 M
|
$125.96 M
|
$124.19 M
|
$122.57 M
|
$126.69 M
|
$124.52 M
|
$116.14 M
|
$106.88 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
